How to Start an OTC Topical Gel and Ointment Manufacturing Unit

The topical gel manufacturing business sits at the intersection of pharmaceutical manufacturing and consumer health — a sector with durable demand, high gross margins, and a relatively accessible entry point for technically qualified entrepreneurs. OTC topical gels and ointments include pain-relief gels, antifungal creams, antiseptic ointments, and moisturising medicated products — products sold daily in pharmacies across every market without a prescription. For a founder with a pharmaceutical or chemical engineering background, or access to a qualified formulation partner, this is one of the most viable manufacturing businesses to start with limited capital. This guide covers everything you need to plan, set up, and launch an OTC topical semi-solid manufacturing unit: from the real capital requirements and facility design to the regulatory pathway, GMP basics, and how to make your first commercial sales.

Market Overview & Opportunity

The global OTC pharmaceutical market is a multi-hundred-billion-dollar sector, and topical semi-solid dosage forms — gels, creams, ointments, and pastes — represent one of its most stable and consistent segments. Unlike oral dosage forms, topical products are less subject to taste and swallowing issues, are perceived as safer by consumers for self-medication, and are increasingly preferred by pharmacists as an alternative to systemic drugs for localised conditions such as musculoskeletal pain, skin infections, and wound care. In emerging markets across South Asia, the Middle East, Africa, and Southeast Asia, the demand for affordable, locally produced OTC topical products is growing as consumer health awareness increases and imported products remain relatively expensive.

The primary customer segments for a startup OTC topical manufacturer are independent pharmacies and pharmacy chains, hospital and clinic procurement departments, government health procurement programmes, and cosmeceutical distributors serving the border between pharmaceutical and cosmetic topicals. Demand is driven by population growth, ageing demographics increasing the prevalence of musculoskeletal conditions, expanding health insurance coverage, and a secular shift toward self-care and OTC products. According to guidance from the WHO on good manufacturing practices for pharmaceutical products, the technical standards for OTC topical production are well-defined and achievable by a disciplined small-scale manufacturer.

The competitive landscape for a local OTC topical manufacturer is favourable in most emerging markets. Large multinational pharmaceutical companies dominate the branded segment but are uncompetitive on price for commodity OTC products, and most markets have a substantial generic or private-label segment served by local manufacturers. Your competitive advantages as a local startup are: lower-cost production, faster supply chain, willingness to customise formulations, and flexibility on minimum order quantities — advantages that large manufacturers cannot offer pharmacy buyers efficiently.

Investment Breakdown: Starting on Minimum Capital

Starting an OTC topical gel and ointment manufacturing unit requires moderately higher capital than a cosmetics emulsion business, primarily because of the GMP facility requirements imposed by drug manufacturing regulations. The equipment itself — planetary mixers, tube-filling machines, and basic QC instruments — is not prohibitively expensive. The additional cost comes from building or renting a facility that meets GMP standards, obtaining a drug manufacturing licence, and funding the regulatory registration of your first product. Total startup capital for a viable small-scale unit typically ranges from $6,000 to $20,000 depending on the market, equipment condition, and regulatory environment.

The most significant cost-saving lever for a startup is sourcing the planetary mixer or manufacturing vessel from a local stainless steel fabricator rather than importing an equivalent European or Chinese unit. In most markets, a local fabricator can produce a functional 50–200 L jacketed vessel with adequate agitation for 30–50% of the imported price. The trade-off is less sophisticated control instrumentation, but for a startup producing a limited range of simple gel or ointment formulations, a manually controlled local vessel is entirely adequate.

Minimum Equipment List for a Small-Scale Unit

Semi-solid pharmaceutical manufacturing — gels, ointments, creams, and pastes — requires equipment that can heat, mix, homogenise, and cool a viscous mass while maintaining cleanliness and batch integrity. The equipment list for a small OTC topical unit is compact and manageable: the core is a planetary or anchor mixer with a jacketed vessel, supplemented by a tube filler, basic QC instruments, and a pharmaceutical-grade water supply system. Unlike sterile injectable manufacturing, OTC topical production does not require cleanrooms or aseptic filling environments — but it does require GMP-compliant construction materials, controlled environmental conditions, and a defined cleaning and sanitisation programme.

A jacketed semi-solid manufacturing vessel with anchor stirrer — the core piece of equipment for producing OTC topical gels, creams, and ointments at small-batch scale.

Space, Utilities & Infrastructure Requirements

An OTC topical gel and ointment manufacturing unit requires a dedicated space of 400 to 700 square feet at minimum, designed to meet GMP facility standards imposed by drug manufacturing regulations. Unlike food or cosmetic production, pharmaceutical GMP requires specific construction standards: smooth, non-porous, cleanable walls and ceilings (epoxy-painted concrete or ceramic tile are standard), impervious flooring with adequate drainage, and defined zones for production, material storage, QC sampling, and personnel changing. The facility does not need to be a cleanroom — OTC topical products are non-sterile — but it must be demonstrably cleanable, controlled, and documented as such.

Power requirements are modest: a single-phase or small three-phase supply is adequate for a 50–200 L jacketed vessel and associated ancillary equipment. HVAC is required for temperature and humidity control within the production area: most GMP guidelines specify maintaining 18–25°C and relative humidity below 60% in active production areas, both to protect product quality and for personnel comfort. A split-unit air conditioner and a dehumidifier are sufficient for a small unit in most climates.

Utility requirements summary:

• Power — 10–20 kW total connected load for a small unit; single-phase adequate for most starter setups
• Water — Mains supply plus an in-house Purified Water generation system (RO + deionisation); minimum 200 L/day capacity
• Ventilation — General ventilation adequate; no explosion-proof requirement for aqueous gel manufacturing; organic solvent-containing ointment bases require local exhaust ventilation
• Drainage — Dedicated production area drainage for vessel cleaning and spillage; do not share with toilet drainage
• Lighting — Minimum 300 lux at workbench level in production areas; higher for QC sampling stations

Best Products to Start With: Low Regulatory Complexity, High Demand

Choosing your first product in OTC topical manufacturing requires balancing regulatory complexity, raw material availability, market demand, and manufacturing difficulty. The best starter products are those with well-established active ingredients, published pharmacopoeial monographs providing clear quality standards, and a clear, uncrowded market position at a local level. Avoid novel active ingredients, fixed-dose combinations requiring separate regulatory approval, and products with complex stability profiles for your first product line. The three categories below represent the most viable entry points for a new OTC topical manufacturer.

1. NSAID Topical Gels (Diclofenac, Ketoprofen, Ibuprofen)

Anti-inflammatory and analgesic topical gels are the highest-volume OTC topical products sold through pharmacies globally. Diclofenac sodium gel 1% and 2% are established generic products with clear pharmacopoeial specifications, widely available active ingredients, and a proven carbomer-based gel formulation technology. The manufacturing process is relatively straightforward, stability data is well-understood in the published literature, and the market demand is consistent and growing with ageing populations. This is the most common entry product for a new topical OTC manufacturer in South Asia and the GCC.

2. Antifungal Creams (Clotrimazole, Miconazole, Ketoconazole)

Antifungal creams represent a high-frequency, repeat-purchase category driven by the prevalence of dermatophyte infections in warm, humid climates. Clotrimazole 1% cream is the most widely recognised generic, with established formulation technology, a clear regulatory classification as an OTC product in most markets, and a straightforward oil-in-water cream manufacturing process. Shelf life is typically 24–36 months, and the product has excellent chemical stability in standard packaging.

3. Antiseptic Ointments (Mupirocin, Bacitracin, Neomycin/Polymyxin Combinations)

Antibiotic ointments for wound care and skin infections are consistently demanded in pharmacy settings, particularly in markets with high incidence of minor skin infections and limited access to systemic antibiotics. Mupirocin 2% ointment (petrolateum base) is a widely registered generic in many markets and uses simple ointment base technology. However, note that antibiotic topicals are classified as prescription-only products in some regulatory jurisdictions — verify the OTC status in your target market before planning production.

For a detailed overview of the product categories and formulation technology within this sector, the Global Formulation pharmaceuticals and health care resource section provides category-level technical guidance for manufacturers at all stages.

Raw Material Sourcing Strategy

OTC topical gel and ointment formulations draw from three principal raw material categories: the active pharmaceutical ingredient (API), the base or vehicle system (gel polymers, ointment bases, emulsion components), and functional excipients (preservatives, pH adjusters, chelating agents, solubilisers). Each category has distinct sourcing requirements, quality standards, and documentation expectations that differ from cosmetic raw material sourcing. API procurement in particular is regulated in most markets — suppliers must provide a Drug Master File (DMF) reference or Certificate of Suitability (CoS) for APIs used in pharmaceutical products.

Key sourcing decisions for a topical OTC startup:

• APIs — Source from established pharmaceutical API manufacturers with full regulatory documentation. For common generics (diclofenac, clotrimazole), multiple local and Indian API suppliers are typically available. Avoid trading companies that cannot provide the original manufacturer's documentation.
• Carbomers and gel polymers — Carbopol/carbomer grades are widely available from regional distributors of Lubrizol or equivalent suppliers. Specify the grade required by your formulation (e.g., Carbopol 940, 974P) as different grades give significantly different viscosity and clarity profiles.
• Ointment bases — White soft paraffin (petrolatum), liquid paraffin, and polyethylene glycols are available from most pharmaceutical excipient distributors. Specify pharmaceutical grade (BP/USP) — cosmetic or industrial grades do not meet the quality standards required.
• Preservatives — Methylparaben, propylparaben, benzyl alcohol, and chlorocresol are standard pharmaceutical topical preservatives. Ensure you source pharmaceutical grade with full CoA documentation.
• Purified Water — Produce in-house using your validated water system — do not source from external suppliers for pharmaceutical production.

The EMA quality guidelines for pharmaceutical products provide an internationally recognised framework for excipient qualification and supplier assessment that is applicable even for manufacturers in non-EU markets who wish to align with global standards.

Manufacturing Process Overview

OTC topical semi-solid manufacturing covers three distinct process types depending on the product: aqueous gel preparation (for carbomer-based gels), ointment preparation (for petrolatum or PEG-based bases), and emulsion-based cream preparation (for oil-in-water or water-in-oil cream vehicles). The choice of process is determined by the formulation, which is in turn determined by the API's physicochemical properties — its solubility, stability at elevated temperature, and compatibility with the base system. The general sequence for the most common type (aqueous carbomer gel with an API in solution or suspension) is described below.

1. Water Phase Preparation — Disperse the carbomer polymer into the required quantity of Purified Water using a high-shear mixer or by slow sifting with continuous stirring. Allow the carbomer to hydrate fully — this typically takes 30–60 minutes — to produce a clear, lump-free dispersion. Do not heat at this stage for heat-sensitive systems.
2. API Dissolution or Dispersion — Dissolve the API in a portion of Purified Water or a co-solvent (e.g. propylene glycol, ethanol) at room temperature or with gentle warming, depending on the API's solubility profile. If the API is insoluble, prepare a fine suspension using a colloid mill or high-shear mixer.
3. Addition of Excipients — Add water-soluble excipients (chelating agents such as EDTA, preservatives, humectants) to the carbomer dispersion and mix thoroughly.
4. Neutralisation — Add a neutralising agent (typically triethanolamine or sodium hydroxide solution) slowly and with continuous mixing. The carbomer network builds viscosity rapidly upon neutralisation — control the addition rate to avoid local over-neutralisation. Target pH is typically 6.0–7.5 for topical gels.
5. API Incorporation — Add the dissolved or dispersed API to the neutralised gel base and mix at low speed to achieve uniform distribution without introducing air.
6. Homogenisation — Pass the gel through a rotor-stator homogeniser to achieve a smooth, uniform texture and reduce any agglomerates. For ointments, a triple-roll mill is the traditional equipment for achieving homogeneity, though modern high-shear planetary mixers can substitute at small scale.
7. QC Sampling and Adjustment — Sample the batch for pH, viscosity, and appearance. Adjust pH if outside specification. Do not adjust viscosity by adding water after neutralisation — if viscosity is too high, the neutralisation ratio or carbomer concentration in the next batch should be adjusted.
8. Filling — Transfer the finished semi-solid to the tube-filling machine. Fill tubes to the declared net weight, crimp seal the tail end, and batch-code each tube. For aluminium tubes, ensure the lacquer lining is compatible with the formulation — uncoated aluminium will react with acidic formulations or APIs containing reactive functional groups.

Carbomer polymer and pharmaceutical-grade active ingredient raw materials prepared for gel manufacturing — each must be sourced from approved suppliers with full pharmacopoeial documentation.

Quality Control & Testing for Small Manufacturers

Quality control for OTC topical drug products operates under pharmaceutical GMP requirements — a higher standard than cosmetic QC. Every batch must be tested against a defined product specification before release, and a sample must be retained for the duration of the product's shelf life plus one year. In-process controls (temperature, pH, viscosity during manufacturing) are as important as finished product testing and must be documented in the batch manufacturing record for every batch. Third-party microbiology testing is required for preservative efficacy validation, routine bioburden testing, and any stability testing that generates microbiological data.

At startup, HPLC assay testing is the most significant QC cost item that cannot be performed in-house without major capital investment. The practical solution is to establish a relationship with a contract analytical laboratory for batch release HPLC testing, and to conduct all in-process and physical QC tests in-house. As production volume grows, in-house HPLC becomes economically justified — expect to spend $8,000–$25,000 for a basic analytical HPLC system. Until then, factor contract laboratory costs of $50–$200 per assay test into your cost of goods.

Packaging & Branding on a Budget

OTC topical drug products are packaged in a narrow range of primary container formats compared to cosmetics. The dominant format for gels and ointments is the collapsible tube — either aluminium or multi-layer laminate (aluminium/plastic laminate or all-plastic). Tube sizes range from 5 g to 100 g, with 15 g, 20 g, 30 g, and 50 g being the most common pharmacy-shelf sizes. The choice of aluminium versus laminate tube is a formulation compatibility and cost decision: aluminium tubes are lower cost but require an internal lacquer lining for compatibility with acidic or reactive formulations; laminate tubes are more compatible across a wider range of formulations but carry a 30–60% cost premium.

Mandatory Labelling Requirements

Drug product labels carry more mandatory information than cosmetic labels and are regulated more strictly. At minimum, an OTC topical drug label must include: approved product name (generic and brand), active ingredient and strength, full excipient declaration (including allergens), net weight, dosage instructions, indications, contraindications and warnings, storage conditions, manufacturer name and full address, manufacturing licence number, batch number, manufacture date, and expiry date. The label layout and text must be approved by the regulatory authority as part of the product registration dossier before commercial production begins.

Carton and Secondary Packaging

Most OTC topical products are sold in a folded carton containing the tube plus a package insert (patient information leaflet). The package insert is a regulatory requirement in most markets and must be approved as part of the product dossier. For a startup, print-on-demand cartons from a local pharmaceutical packaging printer are the most cost-effective option at small volumes — minimum order quantities of 500–1,000 units are typically available at reasonable prices. Ensure the carton material (typically 300–350 gsm SBS board) and the printing inks are compatible with pharmaceutical use and do not migrate into the product.

Brand vs. Generic Label Positioning

Many OTC topical manufacturers start by supplying product under a retailer's or pharmacy chain's private label before investing in their own consumer brand. This approach generates volume and cash flow quickly, avoids marketing costs, and allows the manufacturer to validate their production quality against buyer expectations before investing in brand development. The technical quality of the product is what wins and retains private-label contracts in the pharmaceutical sector — price alone is rarely sufficient without consistent quality and supply reliability. Explore the consultant support options available at Global Formulation for guidance on navigating your first OTC product positioning.

Licensing, Registration & Regulatory Compliance

OTC topical gel and ointment manufacturing sits under pharmaceutical regulation in virtually every market — not cosmetic regulation. This is the single most important distinction for a startup founder to understand: the moment your product label carries a therapeutic claim (pain relief, antifungal, wound healing, anti-inflammatory), the product is legally a drug and subject to drug manufacturing and product registration requirements. The relevant regulatory bodies for key markets are: DRAP in Pakistan, CDSCO in India, SFDA in Saudi Arabia, HAAD/DHA in UAE, and MoH equivalents across other GCC states.

Regulatory Pathway — Priority Order

1. Business and Tax Registration — Register your legal entity and obtain a tax identification number. This underpins all subsequent regulatory applications.
2. Drug Manufacturing Licence (Site Licence) — Apply to the national drug regulatory authority for a manufacturing licence for non-sterile topical dosage forms. Requirements include: a GMP-compliant facility inspection, appointment of a qualified person (pharmacist or licensed technical director), documented SOPs for production, QC, and hygiene, and a validated water system. Timeline: 2–6 months typically.
3. Product Registration Dossier — For each product you intend to sell, submit a registration dossier containing: product formulation details, manufacturing process description, analytical specifications and test methods, stability data, and proposed labelling. In markets following the CTD (Common Technical Document) format, a full quality dossier is required. Timeline: 3–12 months per product.
4. GMP Compliance Certificate — Some markets and export channels require a GMP compliance certificate or WHO GMP certificate issued after facility inspection. Apply for this only after your manufacturing licence is in place and you have completed at least 3 production batches under GMP conditions.
5. Export Regulatory Requirements — For export to GCC, African, or Southeast Asian markets, a Certificate of Free Sale (CFS) from your national drug authority and a COPP (Certificate of Pharmaceutical Product) issued to WHO format are typically required by the importing country's drug authority.

Pricing Strategy & Margin Expectations

OTC topical pharmaceutical products carry higher gross margins than most commodity chemical products, reflecting the value added by regulatory compliance, quality assurance, and the therapeutic efficacy of the product. Typical gross margins for a small-scale OTC topical manufacturer supplying pharmacy distributors range from 45% to 65%, with the upper end achievable on branded or proprietary formulations. Generic product supply under private label typically operates at 40–55% gross margin.

Unit Cost Structure

For a typical 30 g NSAID gel in an aluminium tube, the cost structure for a startup manufacturer typically breaks down as follows:

• API (diclofenac sodium): $0.08–$0.20 per unit (highly variable with batch size and supplier)
• Excipients (carbomer, TEA, propylene glycol, preservative): $0.05–$0.12 per unit
• Packaging (tube, carton, label, insert): $0.20–$0.45 per unit
• Labour (pro-rated at small-scale): $0.10–$0.20 per unit
• QC and testing (including contract laboratory): $0.05–$0.15 per unit
• Overheads (rent, utilities, regulatory compliance amortised): $0.08–$0.20 per unit
• Total cost: approximately $0.56–$1.32 per 30 g tube

At a 50% gross margin, ex-factory pricing of $1.12–$2.64 per tube is achievable. Comparative imported generic diclofenac gel at pharmacy retail level in most South Asian markets sells at $0.80–$2.50 per 30 g tube — meaning a locally manufactured equivalent can be price-competitive while still generating sustainable margins for the manufacturer.

Handling Price Pressure from Distributors

Pharmaceutical distributors routinely negotiate hard on price, especially for generic products where multiple suppliers exist. Protect your margins by differentiating on delivery reliability, minimum order flexibility, and product consistency rather than competing solely on price. A distributor who experiences two delivery failures from a cheaper supplier is typically open to a slightly higher-priced local manufacturer who delivers on time every time. Price is the entry ticket; reliability is what retains the contract.

Finding Your First 20 Customers

The commercial pathway for a new OTC topical manufacturer runs directly through pharmacies and pharmaceutical distributors. Unlike consumer product categories where social media and retail platforms provide accessible sales channels, pharmaceutical products require regulatory approval before they can be stocked, and buyers make supplier decisions based on licence verification, product documentation, and sample evaluation — not branding. Your first customers will be won through direct, documented, compliance-first conversations with pharmacy buyers and distribution company procurement managers.

Step 1: Build Your Documentation Package

Before approaching any buyer, prepare a product documentation package: copy of your drug manufacturing licence, product registration certificate for each product, current batch Certificate of Analysis, and a sample unit. Pharmacy buyers and distributors are required by their own regulatory obligations to verify supplier licences before purchasing. Having your documentation ready demonstrates professionalism and accelerates the buyer's decision timeline significantly.

Step 2: Direct Pharmacy Outreach

Identify the 20–30 highest-volume independent pharmacies and pharmacy chains in your target city. Request a meeting with the buyer or owner, present your product with the documentation package, and offer a trial sample. Focus your pitch on three things: regulatory compliance (you are a licenced manufacturer), product quality (share your CoA), and price advantage versus the equivalent imported product. Do not over-promise on distribution breadth or product range — underpromise and overdeliver in the first 90 days.

Step 3: Target Regional Pharmaceutical Distributors

A single regional pharmaceutical distributor managing 200–500 pharmacy accounts can transform your sales volume within months. Getting on a distributor's product list requires product samples, regulatory documentation, and a competitive price list with defined credit terms. Most distributors will request a minimum of 60-day payment terms — factor this into your working capital planning before agreeing. The manufacturing and distribution strategy guide at Global Formulation provides a practical framework for structuring these early distribution relationships.

Step 4: Government and Institutional Procurement

Government health ministries, hospital procurement departments, and NGO health programmes represent significant volume buyers for OTC pharmaceutical products in most emerging markets. Access to these channels requires registration on approved vendor lists, competitive pricing, and a track record of supply reliability. This is a year-two or year-three objective for most startups — but begin the registration process early, as vendor qualification can take 6–12 months from application to first order.

When and How to Scale Up Your Production

Scaling up a topical pharmaceutical manufacturing unit is a regulated event, not just an operational decision. In most markets, a significant change to your production equipment, batch size, or facility requires notification to or approval from the drug regulatory authority — a process called a variation or post-approval change. Planning your scale-up pathway from the outset — knowing which changes require regulatory pre-approval versus simple notification — avoids expensive production stoppages when your demand outgrows your initial capacity.

The practical signals that a startup is ready to scale:

• Sustained monthly orders from three or more independent distributor or pharmacy accounts
• Production running at 80%+ capacity utilisation for at least 3 consecutive months
• Working capital reserves sufficient to fund 3 months of higher raw material inventory
• At least 2 product registrations in place, providing a product range that justifies larger batch sizes

Next investments at scale-up typically include: a 500–2,000 L jacketed planetary mixer, a semi-automatic or automatic tube-filling line with integrated checkweighing, an in-house HPLC analytical system to reduce contract laboratory costs, and potentially a dedicated stability chamber for formal ICH stability studies. The sustainable manufacturing pathways resource at Global Formulation covers how scaling manufacturers can incorporate green chemistry principles from the outset — relevant for OTC topical manufacturers considering water reduction, biodegradable excipients, and reduced packaging waste.